Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 26, 2016 07:30 ET | Source: Lisata Therapeutics

Caladrius Biosciences Licenses Cell Therapy Technology for Ovarian Cancer and Subleases Irvine Facility to AiVita Biomedical

BASKING RIDGE, N.J., May 26, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development and...
May 12, 2016 16:05 ET | Source: Lisata Therapeutics

Caladrius Biosciences Receives Orphan Drug Designation for CLBS03 to Treat Type 1 Diabetes

BASKING RIDGE, N.J., May 12, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development and...
May 09, 2016 07:30 ET | Source: Lisata Therapeutics

Caladrius Biosciences to Present at Multiple Upcoming May Conferences

BASKING RIDGE, N.J., May 09, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development and...
May 05, 2016 16:14 ET | Source: Lisata Therapeutics

Caladrius Biosciences Reports 2016 First Quarter Financial Results

Total Quarterly Revenues Increase 136% versus Prior Year Conference Call Begins Today at 5:00 pm Eastern Time BASKING RIDGE, N.J., May 05, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc....
April 28, 2016 07:30 ET | Source: Lisata Therapeutics

Caladrius Biosciences to Host 2016 First Quarter Financial Results Conference Call on May 5 at 5:00 pm Eastern Time

BASKING RIDGE, N.J., April 28, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development...
April 20, 2016 07:30 ET | Source: Lisata Therapeutics

Caladrius Biosciences to Present at Multiple Upcoming April Conferences

BASKING RIDGE, N.J., April 20, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development...
April 18, 2016 07:30 ET | Source: Lisata Therapeutics

Caladrius Reaches Agreement with Japanese Regulators on Development Plan for CD34 Cell Therapy for Critical Limb Ischemia

BASKING RIDGE, N.J., April 18, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the “Company”), a leading cell therapy company combining an industry-leading...
March 29, 2016 07:30 ET | Source: Lisata Therapeutics

Caladrius Biosciences Announces First Subject Treated in CLBS03 Type 1 Diabetes Phase 2 Trial

BASKING RIDGE, N.J., March 29, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences (NASDAQ:CLBS), (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development and...
March 17, 2016 07:30 ET | Source: Lisata Therapeutics

Caladrius Biosciences to Present at Multiple Upcoming March Conferences

BASKING RIDGE, N.J., March 17, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius”), a cell therapy company combining an industry-leading development and manufacturing...
March 15, 2016 16:04 ET | Source: Lisata Therapeutics

Caladrius Biosciences Announces 2015 Fourth Quarter and Full Year Financial Results

Quarterly Growth of 43% and Annual Growth of 25% versus Prior Year Driven by PCT Clinical Services Revenues Conference Call Begins Today at 5:00 pm Eastern Time BASKING RIDGE, N.J., March 15,...